Edition:
United States

Biosyent Inc (RX.V)

RX.V on TSX Venture Exchange

8.85CAD
--
Change (% chg)

-- (--)
Prev Close
$8.85
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
14,540
52-wk High
$9.25
52-wk Low
$6.90

Latest Key Developments (Source: Significant Developments)

BioSyent reports Q2 earnings per share C$0.11
Wednesday, 16 Aug 2017 08:00am EDT 

Aug 16 (Reuters) - BioSyent Inc :BioSyent releases Q2 AND H1 2017 results.Q2 earnings per share C$0.11.Q2 revenue rose 29 percent to C$5.636 million.  Full Article

Biosyent Q1 earnings per share C$0.06
Thursday, 25 May 2017 08:00am EDT 

May 25 (Reuters) - Biosyent Inc ::Biosyent releases Q1 2017 results.Q1 earnings per share C$0.06.Q1 revenue rose 1 percent to C$3.821 million.  Full Article

Biosyent reports Q1 earnings per share C$0.06
Thursday, 25 May 2017 08:00am EDT 

May 25 (Reuters) - Biosyent Inc :Biosyent releases Q1 2017 results.Q1 earnings per share C$0.06.Q1 revenue rose 1 percent to c$3.821 million.  Full Article

Biosyent extends in-license agreement for cathejell
Thursday, 20 Apr 2017 04:00pm EDT 

April 20 (Reuters) - Biosyent Inc ::Biosyent extends in-license agreement for cathejell(r).Biosyent Inc - extended its license, distribution and supply agreement with its European partner, Pharmazeutische Fabrik Montavit GES.M.B.H..Extensio gives Biosyent Pharma exclusive Canadian rights to cathejell jelly 2 pct product until march 31, 2024.  Full Article

Biosyent Q4 earnings per share C$0.08
Wednesday, 15 Mar 2017 08:00am EDT 

Biosyent Inc : Biosyent releases results for fourth quarter and full year 2016 . Q4 earnings per share C$0.08 . Q4 revenue rose 30 percent to c$5.01 million .Biosyent Inc - as at December 31, 2016, company had cash, cash equivalents, and short term investments totalling C$13.7 million.  Full Article

Biosyent Q2 fully diluted EPS $0.07
Friday, 12 Aug 2016 08:00am EDT 

Biosyent Inc : Q2 2016 net revenues of $4.4 million, up 22% versus Q2 2015 .Biosyent Inc says Q2 fully diluted EPS was $0.07.  Full Article

BioSyent Q1 earnings per share C$0.07
Friday, 27 May 2016 08:00am EDT 

BioSyent Inc : BioSyent releases Q1 2016 results . Q1 earnings per share C$0.07 .Q1 revenue rose 14 percent to C$3.772 million.  Full Article

Biosyent signs distribution agreement for new cardiovascular products
Wednesday, 25 May 2016 12:53pm EDT 

Biosyent Inc: Biosyent signs exclusive distribution agreement for two new cardiovascular products . Intends to submit dossier seeking marketing approval of products to Health Canada in 2016 .Forecasts that the new products will add approximately CAD $20 million to overall revenue of company when they reach "peak sales".  Full Article

BioSyent Inc receives Health Canada approval for new urgent care product using aguettant system
Thursday, 5 May 2016 08:00am EDT 

BioSyent Inc:Says its subsidiary, BioSyent Pharma Inc has received approval from Health Canada for a new urgent care product, phenylephrine hydrochloride injection in Aguettant System pre-filled syringe, for use in hospitals and acute care settings.  Full Article

BRIEF-BioSyent reports Q2 earnings per share C$0.11

* Q2 revenue rose 29 percent to C$5.636 million Source text for Eikon: Further company coverage: